Synthetic DNA Market Projected to Reach USD 7.72 Billion by 2034 at 18.02% CAGR

The global Synthetic DNA market was valued at USD 1.44 billion in 2025 and is estimated at USD 1.74 billion in 2026, according to Polaris Market Research. The market is projected to reach USD 7.72 billion by 2034, growing at a CAGR of 18.02% from 2026 to 2034. It covers commercially supplied DNA products whose sequences are deliberately specified and manufactured, including custom DNA oligonucleotides, DNA pools, gene fragments, verified genes, libraries and custom constructs. Growth is supported by faster availability of DNA fragments, access to longer and more complex constructs, the development of enzymatic DNA synthesis, increasing use of sequence design automation and growing demand for verified DNA across research, diagnostics and therapeutic development.

Synthetic DNA Market Growth and Industry Outlook

Twist Bioscience added eligible DNA fragments to its Express delivery offering in 2025, with selected products starting from USD 0.07 per base pair, shortening the time between sequence design and laboratory validation. Ansa Biotechnologies announced a 50 kilobase sequence-perfect clonal DNA product in 2025, and in September 2026 Integrated DNA Technologies and Ansa expanded their partnership to enable direct ordering of complex constructs up to 50 kb, with more than 400 institutions across 33 countries having ordered constructs of up to 49.1 kb. In May 2026, Twist also expanded its clonal gene portfolio to sequences of up to 7,000 base pairs, citing AI-guided protein design and nucleic acid therapeutics as demand drivers.

Key Market Drivers and Emerging Trends

Polaris Market Research identifies faster fragment availability and longer verified constructs as the main drivers, with commercial DNA oligos for diagnostics and specialized constructs for synthetic genomics projects presented as opportunities. Enzymatic DNA synthesis is one of the principal areas expanding DNA-writing capability: DNA Script's SYNTAX benchtop platform supports on-demand production, while Ansa applies an enzymatic approach to long clonal DNA. In May 2026, 4basebio announced an enzymatic ssDNA platform for templates of up to 10,000 nucleotides, and Ribbon Bio launched MiroSynth Cell-Free DNA, which avoids bacterial cloning. Screening and quality-control requirements are the principal restraint, as providers must verify sequences, screen customers and document orders.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/synthetic-dna-market

Segment and Application Insights

By product format, DNA oligonucleotides and pools accounted for 54.42% of the market in 2025. Gene fragments are expected to grow at a 19.42% CAGR, verified genes accounted for 20.13% of the market in 2025, and custom constructs and libraries are projected to record a 22.46% CAGR. By synthesis technology, chemical synthesis accounted for 56.72% in 2025, while enzymatic synthesis is projected to register a 22.31% CAGR. By application, research and engineering represented 43.42% of the market in 2025, therapeutic development held a 32.72% share and diagnostics is expected to record a 17.84% CAGR. Pharmaceutical and biotechnology companies accounted for 41.26% of end-use demand in 2025, and academic and public research institutes are expected to register a 14.86% CAGR.

Regional Market Perspective

North America was the largest regional market in 2025, holding 39.68% of the global market, supported by established suppliers, biotechnology companies and research institutions. Europe held 25.14%, supported by life-sciences capabilities and specialized synthesis providers such as DNA Script. Asia Pacific is expected to grow at a 20.12% CAGR, and in July 2026 DNA Script entered a distribution agreement with Imperial Life Sciences to expand access to its on-demand synthesis technology in India. Latin America accounted for 5.72% of the global market in 2025 and Middle East & Africa for 4.70%, with international supplier networks and distribution arrangements shaping regional access.

Competitive Landscape

Polaris Market Research notes that competition centers on sequence acceptance, delivery format, quality evidence, turnaround time and workflow integration. In its qualitative assessment, which is not a revenue ranking, Polaris positions Twist Bioscience, Integrated DNA Technologies, Thermo Fisher Scientific and GenScript Biotech as market leaders, with Eurofins Scientific, LGC Biosearch Technologies, Merck KGaA, Agilent Technologies and Azenta as established players. Twist Bioscience, whose offering spans gene fragments and verified genes, launched early access to Complex Genes of 300 to 7,000 base pairs in May 2026, while Agilent supplies SurePrint HiFi pools of custom-designed DNA oligonucleotides for screening and library construction.

Future Market Outlook

Looking ahead, the Synthetic DNA market is projected to rise from USD 1.74 billion in 2026 to USD 7.72 billion by 2034, according to Polaris Market Research. Polaris cautions that technical capability and market realization are not the same: new chemistry, longer constructs and faster delivery create potential demand, but revenue depends on repeat customer purchases. Progress in enzymatic DNA synthesis and custom constructs will therefore be assessed alongside delivery reliability, production capacity and verification requirements, while suppliers balance fast delivery with the screening and quality controls that govern DNA orders.

More Trending Latest Reports By Polaris Market Research:

Hydrocolloids Market

Adhesives And Sealants Market

Power Plant Boilers Market

SUV Market

Adhesives And Sealants Market

Otoscope Market

Test and Measurement Equipments Market

Automotive E-Compressor Market

Benign Prostatic Hyperplasia Surgical Treatment Market